Xvivo Perfusion AB (XVIVO) Price & Analysis

Compare

1 Followers

XVIVO Stock Chart & Stats

Day’s Range― - ―

52-Week Rangekr238.20 - kr547.00

Previous CloseN/A

Volume6.25K

Average Volume (3M)61.92K

Market Cap

$10.05B

Enterprise Valuekr4.35B

Total Cash (Recent Filing)$315.87M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)69.4

Beta1.15

Next Earnings

Jul 11, 2025

EPS Estimate

0.94

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding31,499,470

10 Day Avg. Volume59,102

30 Day Avg. Volume61,919

Financial Highlights & Ratios

PEG Ratio2.41

Price to Book (P/B)3.78

Price to Sales (P/S)0.00

P/FCF Ratio-52.41

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$392.49

Price Target Upside31.62% Upside

Rating ConsensusHold

Number of Analyst Covering2

Xvivo Perfusion AB News

PremiumCompany Announcements

XVIVO Perfusion AB Wins 2025 SACC-USA Business Award for U.S. Market Growth

2d ago

PremiumCompany Announcements

Xvivo Perfusion AB Reports Q1 2025 Earnings Growth

2M ago

PremiumPre-Earnings

Is XVIPF a Buy, Before Earnings?

2M ago

PremiumThe Fly

Xvivo Perfusion downgraded to Sell from Buy at Danske Bank

3M ago

PremiumThe Fly

Xvivo Perfusion upgraded to Buy from Hold at Pareto

3M ago

PremiumCompany Announcements

XVIVO Perfusion AB Reports Strong 2024 Growth

5M ago

PremiumPre-Earnings

XVIPF Earnings this Week: How Will it Perform?

5M ago

PremiumThe Fly

Xvivo Perfusion downgraded to Hold from Buy at Pareto

5M ago

See All SE:XVIVO News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

4.01%

Mutual Funds

― Other Institutional Investors

93.52% Public Companies and

Individual Investors

Detailed Ownership Overview >

XVIVO FAQ

What was Xvivo Perfusion AB’s price range in the past 12 months?

Xvivo Perfusion AB lowest stock price was kr238.20 and its highest was kr547.00 in the past 12 months.

What is Xvivo Perfusion AB’s market cap?

Xvivo Perfusion AB’s market cap is $10.05B.

When is Xvivo Perfusion AB’s upcoming earnings report date?

Xvivo Perfusion AB’s upcoming earnings report date is Jul 11, 2025 which is in 26 days.

How were Xvivo Perfusion AB’s earnings last quarter?

Xvivo Perfusion AB released its earnings results on Apr 24, 2025. The company reported -kr0.39 earnings per share for the quarter, missing the consensus estimate of kr0.785 by -kr1.175.

Is Xvivo Perfusion AB overvalued?

According to Wall Street analysts Xvivo Perfusion AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Xvivo Perfusion AB pay dividends?

Xvivo Perfusion AB does not currently pay dividends.

What is Xvivo Perfusion AB’s EPS estimate?

Xvivo Perfusion AB’s EPS estimate is 0.94.

How many shares outstanding does Xvivo Perfusion AB have?

Xvivo Perfusion AB has 31,499,470 shares outstanding.

What happened to Xvivo Perfusion AB’s price movement after its last earnings report?

Xvivo Perfusion AB reported an EPS of -kr0.39 in its last earnings report, missing expectations of kr0.785. Following the earnings report the stock price went up 6.88%.

Which hedge fund is a major shareholder of Xvivo Perfusion AB?

Currently, no hedge funds are holding shares in SE:XVIVO

Company Description

Xvivo Perfusion AB

Xvivo Perfusion AB (XVIVO) is a biotechnology company based in Sweden that specializes in the development and commercialization of advanced medical technologies for organ transplantation. The company's core products include perfusion systems and solutions designed to preserve, evaluate, and transport organs outside the body, enhancing the viability and success of transplants. XVIVO's innovative solutions are aimed at optimizing the transplantation process and increasing the availability of viable organs for patients in need.

XVIVO Company Deck

XVIVO Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a strong quarter with significant growth in the Thoracic and Liver segments, complemented by successful heart trials and strategic acquisitions. However, challenges in the Abdominal and Services segments, along with hurdles in launching Kidney Assist Transport in the U.S., balanced the overall sentiment.Read More>

XVIVO Stock 12 Month Forecast

Average Price Target

kr392.49

▲(31.62%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"133":"kr133","460":"kr460","214.75":"kr214.8","296.5":"kr296.5","378.25":"kr378.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":459.9999998845308,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr460.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":392.4919535316,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr392.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":324.9999999184185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr325.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[133,214.75,296.5,378.25,460],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Mar<br/>2023","9":"Jun<br/>2023","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,444,445.230769221887,446.461538443774,447.69230766566096,448.92307688754795,450.15384610943494,451.3846153313219,452.61538455320886,453.84615377509584,455.07692299698283,456.3076922188698,457.5384614407568,458.7692306626438,{"y":459.9999998845308,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,444,440.0378425793538,436.0756851587077,432.1135277380615,428.1513703174154,424.1892128967692,420.2270554761231,416.2648980554769,412.3027406348308,408.3405832141846,404.3784257935385,400.4162683728923,396.4541109522462,{"y":392.4919535316,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,444,434.84615383987835,425.6923076797567,416.538461519635,407.38461535951336,398.2307691993917,389.07692303927007,379.9230768791484,370.7692307190268,361.61538455890513,352.46153839878343,343.3076922386618,334.15384607854014,{"y":324.9999999184185,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":179,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":134,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":169.8,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":195.6,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":186.8,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":227.5,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":235,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":244,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":306,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":286,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":286,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":444,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >